Showing results filtered by:
5 Results
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial to evaluate an investigational preventative vaccine for Epstein-Barr virus (EBV). EBV is the primary cause of infectious mononucleosis and is associated with certain cancers and autoimmune diseases. The Phase 1 study, which will be conducted at
Published: May 6, 2022
The Allergy & Immunology (A&I) Fellowship Program provides trainees with high-quality clinical and research skills prepares them to successfully pursue careers in academic medicine. Graduates are listed with their NIH mentor and where they went to work after graduation.
Last Reviewed: September 3, 2024
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), reaffirms our commitment to developing safe and effective medical tools against malaria, and, in the words of this year’s World Malaria Day theme, “Harnessing innovation to reducing the malaria disease burden and saving lives.”
Published: April 25, 2022
A NIAID-supported Phase 3 clinical trial evaluating an investigational COVID-19 vaccine called AZD1222 will enroll around 30,000 adult volunteers.
Published: August 31, 2020
A fourth Phase 3 NIH clinical trial evaluating an investigational vaccine for coronavirus disease 2019 (COVID-19) has begun enrolling adult volunteers.
Published: September 23, 2020